Updates

Clinigen - Trial services to grow at 17% annual clip

December 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Numis has just released a weighty 60-page note on Clinigen, initiating the shares with a Buy and 240p target. Not much new news apart from the expected rates of growth. The broker looks for 17% organic compound growth for Clinigen's two services businesses (Clinigen CTS and GAP) in the next three years (2012-2015) as the use of comparator drugs in clinical trials continues to grow. It adds that the logistical and control requirements for clinical trial supplies are already governed by a swathe of regulations; two new guidelines over the next five years will continue to polarise the work into the hands of the largest players.More and more clinical trials are also focused on diseases with high unmet medical need, such as cancer and ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Lavendon Group

CSR

Clinigen (November 2016)

Clinigen (October 2016)

Clinigen (October 2015)

Clinigen (August 2015)

Clinigen - Completes £225m Idis acquisition (June 2015)

Clinigen (April 2015)

Clinigen (February 2015)

Clinigen - Acquires speciality products (September 2014)

Clinigen - Company reassures investors with trading update (August 2014)

Clinigen (March 2014)

Clinigen - Growing rapidly into valuation (February 2014)

Clinigen - On lookout for 3-5 more deals (November 2013)

Clinigen - Another upgrade to forecast (September 2013)

Clinigen - First of half a dozen deals (April 2013)

Clinigen - Acquisition anticipated in March (March 2013)

Clinigen - New issue growing like topsy (November 2012)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X